| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer,...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Context Therapeutics (NASDAQ:CNTX) through any online brokerage.
Other companies in Context Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Context Therapeutics has a consensus price target of $5.69.
The stock price for Context Therapeutics (NASDAQ: CNTX) is $0.3008 last updated October 1, 2026 at 1:31 AM EDT.
There are no upcoming dividends for Context Therapeutics.
Context Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Context Therapeutics.
Context Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
